Syndicate Bio, a trailblazer in African health innovation, has unveiled Direct by Syndicate Bio, a groundbreaking AI-driven genetic testing and precision medicine service in Nigeria. This launch marks the inauguration of a cutting-edge sequencing laboratory in Lagos, solidifying the company’s commitment to providing personalized healthcare solutions to Nigeria’s vast population of 200 million and beyond.
The realm of precision medicine, which tailors treatments to individuals based on their genetic composition, has long been hindered by a significant data disparity. Historically, genomic data used for medical advancements has predominantly originated from individuals of European descent, rendering many therapies less effective for those of African heritage.
In a bold strategic move to bridge this gap, Syndicate Bio, spearheaded by Dr. Abasi Ene-Obong, is spearheading efforts to revolutionize precision medicine. By establishing local infrastructure, the company aims to collect and analyze genomic data from one of the world’s most diverse populations, unlocking valuable health insights tailored to Nigerians and the broader African community.
Dr. Ene-Obong emphasized the dual nature of Nigeria’s genetic diversity during the launch event, stating, “Nigeria’s diversity presents challenges and opportunities in the realm of precision medicine. The absence of locally sourced genomic data has constrained our ability to prevent, diagnose, and treat diseases effectively. Through Direct, Syndicate Bio harnesses Nigeria’s genetic richness to provide insights that enhance healthcare for Nigerians and the global diaspora, propelling inclusive precision medicine on a worldwide scale.”
Equipped with state-of-the-art next-generation sequencing (NGS) technology and advanced molecular workflows, the Lagos laboratory ensures rapid turnaround times and delivers clinical-grade testing within Nigeria.
The initial service portfolio addresses prevalent health issues in the region, with a keen focus on traits relevant to the population, including essential screenings for sickle cell disease, thalassemia, and G6PD deficiency.
To facilitate the integration of these advanced diagnostics into clinical practice and ensure widespread patient access, Syndicate Bio is establishing the Direct Nigeria Precision Medicine Network (DNPMN). This collaborative network brings together leading local and international healthcare institutions to tackle complex medical cases collectively.
At the core of this network is a collaborative multidisciplinary tumor board established in partnership with the prestigious Roswell Park Comprehensive Cancer Center, a renowned NCI-designated cancer facility in the United States. This initiative enables Nigerian healthcare providers to access expert second opinions and collaborate on treatment strategies for their patients.
Key collaborators include Lakeshore Cancer Center, a premier oncology institution in Nigeria, and the Redus Center for Digestive Health.
Dr. Chukwumere Nwogu, Co-Founder & CEO of Lakeshore Cancer Center, remarked, “Partnering with Syndicate Bio enables us to offer precision oncology services tailored to the unique genetic profiles of our patient population, representing a significant step towards data-driven cancer care in Nigeria.”
Dr. Sai Yendamuri, Chief Strategy Officer at Roswell Park, expressed, “We are privileged to engage in this partnership, underscoring our shared dedication to making precision medicine accessible to underserved communities. The establishment of a joint tumor board will further enhance this collaboration, fostering interdisciplinary dialogue and ensuring patients benefit from the latest medical insights.”
The introduction of Direct by Syndicate Bio transcends mere facility inauguration; it signifies a strategic initiative to lay the groundwork for a future of medicine centered on Africa, driven by indigenous data and empowered by artificial intelligence.
Takeaways:
– Syndicate Bio’s Direct service heralds a new era of precision medicine in Africa, leveraging local genetic data to revolutionize healthcare practices.
– Collaborative networks like the Direct Nigeria Precision Medicine Network are pivotal in ensuring the seamless integration of advanced diagnostics into clinical settings.
– Partnerships with esteemed institutions such as Roswell Park Comprehensive Cancer Center elevate the standard of care and expertise available to patients in Nigeria.
– By prioritizing population-specific health traits, Syndicate Bio is paving the way for tailored medical interventions that cater to the unique genetic profiles of African individuals.